Demant A/S
CSE:DEMANT
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
249.4
371
|
| Price Target |
|
We'll email you a reminder when the closing price reaches DKK.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Demant A/S
Demant A/S
Net Issuance of Common Stock
Demant A/S
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Demant A/S
CSE:DEMANT
|
Net Issuance of Common Stock
-kr2B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-15%
|
|
|
GN Store Nord A/S
CSE:GN
|
Net Issuance of Common Stock
-kr12m
|
CAGR 3-Years
77%
|
CAGR 5-Years
61%
|
CAGR 10-Years
34%
|
|
|
Ambu A/S
CSE:AMBU B
|
Net Issuance of Common Stock
kr0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
V
|
ViroGates A/S
CSE:VIRO
|
Net Issuance of Common Stock
kr13m
|
CAGR 3-Years
67%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Demant A/S
Glance View
Demant A/S, an eminent player in the world of hearing healthcare, finds its roots in Denmark, where it was founded in 1904. The journey, sparked by the compassion of founder Hans Demant who sought ways to improve his wife's hearing experience, has evolved into a global operation focused on improving quality of life through innovative hearing solutions. Demant transcends beyond traditional hearing aids, carving a niche in providing a broad range of hearing healthcare services. These include audiometric equipment, hearing implants, diagnostic instruments, and personal communication applications, all aligned with the mission to help people overcome communication barriers. Key to Demant's strategy is its strong emphasis on research and development, ensuring that it remains at the forefront of technological advancements in audiology. The company monetizes its operations through a combination of cutting-edge product sales and a suite of ancillary services that cater to different segments of the hearing healthcare market. Leveraging a robust distribution network, Demant ensures a wide market reach, with offerings meticulously tailored to meet regional consumer needs. Collaborations with retailers, hospitals, and clinics across the globe amplify its market penetration, driving both revenue and brand loyalty. Additionally, Demant taps into the growing demand for auditory digital health solutions, offering cloud-based services that integrate seamlessly into consumer lifestyles. This multifaceted approach not only diversifies revenue streams but also fortifies Demant's standing as a holistic hearing solutions provider, underpinned by a commitment to enhancing living through auditory wellness.
See Also
What is Demant A/S's Net Issuance of Common Stock?
Net Issuance of Common Stock
-2B
DKK
Based on the financial report for Jun 30, 2024, Demant A/S's Net Issuance of Common Stock amounts to -2B DKK.
What is Demant A/S's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 10Y
-15%
Over the last year, the Net Issuance of Common Stock growth was -257%. The average annual Net Issuance of Common Stock growth rates for Demant A/S have been -3% over the past three years , -12% over the past five years , and -15% over the past ten years .
You don't have any saved screeners yet
